Open Access

HER2+ advanced gastric cancer: Current state and opportunities (Review)

  • Authors:
    • Hui-Hui Hu
    • Sai-Qi Wang
    • Huichen Zhao
    • Zhe-Sheng Chen
    • Xiaojing Shi
    • Xiao-Bing Chen
  • View Affiliations

  • Published online on: February 19, 2024     https://doi.org/10.3892/ijo.2024.5624
  • Article Number: 36
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 have been applied in the treatment of HER2+ AGC, and several novel anti‑HER2 therapies are undergoing preclinical/clinical trials. At present, combination immunotherapy with anti‑HER2 agents is used as the first‑line treatment of this disease subtype. New promising approaches such as chimeric antigen receptor T‑cell immunotherapy and cancer vaccines are also being investigated for their potential to improve clinical outcomes. The current review provides new insights that will guide the future application of anti‑HER2 therapy by summarizing research progress on targeted therapy drugs for HER2+ AGC and combination treatments.
View Figures
View References

Related Articles

Journal Cover

April-2024
Volume 64 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu H, Wang S, Zhao H, Chen Z, Shi X and Chen X: HER2<sup>+</sup> advanced gastric cancer: Current state and opportunities (Review). Int J Oncol 64: 36, 2024.
APA
Hu, H., Wang, S., Zhao, H., Chen, Z., Shi, X., & Chen, X. (2024). HER2<sup>+</sup> advanced gastric cancer: Current state and opportunities (Review). International Journal of Oncology, 64, 36. https://doi.org/10.3892/ijo.2024.5624
MLA
Hu, H., Wang, S., Zhao, H., Chen, Z., Shi, X., Chen, X."HER2<sup>+</sup> advanced gastric cancer: Current state and opportunities (Review)". International Journal of Oncology 64.4 (2024): 36.
Chicago
Hu, H., Wang, S., Zhao, H., Chen, Z., Shi, X., Chen, X."HER2<sup>+</sup> advanced gastric cancer: Current state and opportunities (Review)". International Journal of Oncology 64, no. 4 (2024): 36. https://doi.org/10.3892/ijo.2024.5624